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Introduction
Canakinumab (CAN), a selective, fully human, anti-
interleukin-1b monoclonal antibody, has been shown to
be efficacious in SJIA patients (pts) in 2 phase 3 trials:
Trial 1 (4-wk, randomized placebo [PBO]-controlled)
and Trial 2 (open-label CAN treatment [Part 1] followed by
a randomized PBO-controlled withdrawal phase [Part 2]).
In Trial 1, statistically significantly more CAN than PBO
group pts achieved an adapted pediatric ACR 30 res-
ponse and in Trial 2, CAN allowed successful reduction/
discontinuation of steroids and significantly reduced risk of
flare. Safety profile of CAN was in line with expectations
for a biologic agent in active SJIA. The persistent disabling
features of SJIA and chronic pain can have a negative
impact on health-related quality of life (hrqol). These
outcomes were evaluated in the CAN phase 3 program.
Objectives
To report pt-reported functional ability and hrqol out-
comes from the CAN phase 3 program.
Methods
The phase 3 analysis included 84 pts (CAN, 43; PBO,
41) in Trial 1 and 177 pts in Trial 2 (71 from Trial 1
entered) in Part 1, and 100 rolled into Part 2 (CAN, 50;
PBO, 50). Pt-reported assessments included functional
ability (as measured by the Childhood Health Assessment
Questionnaire [CHAQ©]), pain (measured on a visual
analog scale [VAS] of 0-100 mm as part of the CHAQ©),
and physical (phs) and psychosocial (pss) health status
in 5-18 year old pts., according to the Child Health
Questionnaire-Parent Form (CHQ-PF50).
Results
In Trial 1, CAN treatment was associated with a significant
improvement in CHAQ disability score (estimated differ-
ence [ED] of -0.69 over time vs PBO in the least square
mean [LSM] change from baseline [BL] [p = 0.0002]),
which was ~3.6 × the minimal clinically important differ-
ence of -0.19. The LSM in overall pain intensity were sig-
nificantly lower (both p < 0.0001) in the CAN group vs
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Table 1 Patient- or Parent-reported functional ability and hrqol parameters in Trial 2
Outcome measure, mean (SD) Baseline
CAN, N = 177
End of Part 1
CAN, N = 177
End of Part 2
CAN, N = 50
End of Part 2
PBO, N = 50
CHAQ disability score 1.7 (0.8) 0.74 (0.9) 0.5 (0.9) 0.6 (0.8)
Pain (VAS, 0-100 mm) 66.6 (23.3) 20.2 (25.8) 13.6 (26.9) 17.0 (24.2)
CHQ-PF50 phs score 16.1 (14.3) 37.7 (17.2) 43.6 (17.4) 39.0 (18.1)
CHQ-PF50 pss score 41.6 (11.1) 50.7 (11.1) 53.6 (11.3) 52.7 (9.8)
Results are based on patients with both baseline and post-baseline values. N18 years old.
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PBO both at Day 15 (ED, -46.42) and Day 29 (ED, -41.86).
CHQ-PF50 phs and pss scores also showed significant
improvements over time (ED CAN vs PBO in LSM change
from BL, 12.07 and 7.28; p < 0.005 for both). Improve-
ments in CHAQ disability, CHQ-PF50 phs and pss, and
VAS pain scores were also observed in Trial 2 (Table 1).
Conclusion
Treatment with CAN demonstrated rapid, marked and
continued improvement in patient-reported functional
ability and hrqol of SJIA patients.
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